Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2015-06-06 Director's Dealing
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2015-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-06-06 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 4, 2015, by TG Therapeutics, Inc. It details the submission of matters to a vote of security holders at the company's annual meeting, including election of directors, appointment of independent auditors, and approval of an amendment to the incentive plan. The content focuses on the official results of shareholder votes at the annual meeting. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is about voting results, not the annual report or proxy statement itself, and it is not a brief announcement but a detailed voting result report. Therefore, the correct classification is DVA with high confidence.
2015-06-05 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K, a current report filed with the SEC to announce unscheduled material events or corporate changes. The text mentions press releases about clinical study data and an investor and analyst event presentation. The document includes exhibits of press releases and a presentation but does not contain detailed financial statements or comprehensive financial analysis. The presence of an investor presentation as an exhibit and the nature of the content (clinical data announcements and event presentation) indicate this is primarily an investor presentation update rather than a full financial report or earnings release. The document length is 3020 characters, which is relatively short and consistent with a Form 8-K filing announcing events and attaching presentations. Therefore, the best classification is Investor Presentation (IP).
2015-06-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.